Registry of Hospitalized Patients Treated With Fondaparinux

This study has been completed.
Information provided by:
Brigham and Women's Hospital Identifier:
First received: October 24, 2007
Last updated: September 15, 2009
Last verified: September 2009
Registry of Hospitalized patients at Brigham and Women's Hospital treated with Fondaparinux

Deep Vein Thrombosis
Pulmonary Embolism

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Registry of Hospitalized Patients Treated With Fondaparinux

Resource links provided by NLM:

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Venous Thromboembolism and Bleeding Events [ Time Frame: 90 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: 30 Days ] [ Designated as safety issue: No ]

Enrollment: 220
Study Start Date: July 2007
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Detailed Description:

The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.

Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
BWH hospitalized patients receiving Fondaparinux

Inclusion Criteria:

  • BWH hospitalized patients receiving Fondaparinux
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00549705

Sponsors and Collaborators
Brigham and Women's Hospital
Principal Investigator: Samuel Z Goldhaber, MD Brigham and Women's Hospital
  More Information

Additional Information:
Responsible Party: Samuel Z. Goldhaber, MD, Brigham and Women's Hospital Identifier: NCT00549705     History of Changes
Other Study ID Numbers: 2007-P-001294 
Study First Received: October 24, 2007
Last Updated: September 15, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
Pulmonary Embolism
Deep Vein Thrombosis

Additional relevant MeSH terms:
Pulmonary Embolism
Venous Thrombosis
Cardiovascular Diseases
Embolism and Thrombosis
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Anticoagulants processed this record on May 26, 2016